Zydus gets VAI classification from USFDA for Jarod plant

The health regulator has classified the facility as Voluntary Action Indicated VAI indicating that minor issues were found during an inspection. This inspection at the plant was conducted following the Warning Letter issued on August 29, 2024 by the USFDA. Zydus Lifesciences shares on Thursday ended flat at Rs 935.40 apiece on BSE.

Zydus Lifesciences on Thursday said it has received Establishment Inspection Report from the US health regulator for its Jarod-based injectable manufacturing facility.

The US Food and Drug Administration (USFDA) inspected the plant at Jarod, Vadodara from August 25 to September 5, 2025. The health regulator has classified the facility as Voluntary Action Indicated (VAI) indicating that minor issues were found during an inspection. This inspection at the plant was conducted following the Warning Letter issued on August 29, 2024 by the USFDA. Zydus Lifesciences shares on Thursday ended flat at Rs 935.40 apiece on BSE.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)